Go Pro
NASDAQ:SLXN

Silexion Therapeutics Q2 2025 Earnings Report

Silexion Therapeutics logo
$0.35 +0.00 (+0.11%)
Closing price 09/3/2026 04:00 PM Eastern
Extended Trading
$0.36 +0.01 (+2.10%)
As of 05:59 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Silexion Therapeutics EPS Results

Actual EPS
-$43.20
Consensus EPS
-$31.50
Beat/Miss
Missed by -$11.70
One Year Ago EPS
N/A

Silexion Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Silexion Therapeutics Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Silexion Therapeutics' next earnings date is estimated for Wednesday, November 11, 2026, based on past reporting schedules.

Conference Call Resources

Silexion Therapeutics Earnings Headlines

Before Anthropic becomes impossible to ignore...
Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9.1 billion dollars, according to CNBC. Before any Anthropic IPO arrives, one publicly accessible vehicle already lists Anthropic as its largest holding, available through a regular brokerage with no accredited-investor requirement. History showed how fast access tightened once SpaceX became a headline name. Alexander Green of The Oxford Club says this window is open now.tc pixel
See More Silexion Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Silexion Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Silexion Therapeutics and other key companies, straight to your email.

About Silexion Therapeutics

Silexion Therapeutics (NASDAQ:SLXN) LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

View Silexion Therapeutics Profile